1. Szollar SM, Lee SM. Intravesical oxybutynin for spinal cord injury patients. Spinal Cord 1996;34: 284–7.
2. Lazzeri M, Spinelli M, Zanollo A et al. Intravesical vanilloids and neurogenic incontinence: ten years experience. Urol Int 2004;72:145–9.
3. Guys JM, Haddad M, Planche D et al. Sacral neuromodulation for neurogenic bladder dysfunction in children. J Urol 2004;172(4 Pt 2):1673–6.
4. Van Kerrebroeck PE, Van Voskuilen AC, Lycklama A et al. Long term results of InterStim therapy for voiding disorders demonstrate sustained efficacy and acceptable safety profile. Eur Urol 2004;3:170.
5. Radziszewski P, Dobronski P, Borkowski A. Treatment of nonneurogenic storage and voiding disorders with the chemical deneravtion caused by botulinum toxin A – a pilot study. Neurourol Urodyn 2001;20: 410–2.
6. Schurch B, Stohrer M, Kramer G et al. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 2000;164(3 Pt 1): 692–7.
7. Patki PS, Hamid R, Arumugam K et al. Botulinum toxin-type A in the treatment of drug-resistant neurogenic detrusor overactivity secondary to traumatic spinal cord injury. BJU Int 2006;98:77–82.
8. Del Popolo G, Li Marzi V, Panariello G et al. English botulinum toxin A in the treatment of neurogenic detrusor overactivity. Neurourol Urodyn 2003;22:498.
9. Grosse J, Kramer G, Stohrer M. Success of repeat detrusor injections of botulinum a toxin in patients with severe neurogenic detrusor overactivity and incontinence. Eur Urol 2005;47:653–9.
10. Kessler TM, Danuser H, Schumacher M et al. Botulinum A toxin injections into the detrusor: An effective treatment in idiopathic and neurogenic detrusor overactivity? Neurourol Urodyn 2005;24:231–6.
11. Kuo HC. Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents. Urology 2004;63:868–72.
12. Reitz A, Stohrer M, Kramer G et al. European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol 2004;45:510–5.
13. Schurch B, de Sčze M, Denys P et al. Botulinum toxin a (botox) in neurogenic urinary incontinence: results from a multi-centre randomised controlled trial. Neurourol Urodyn 2004;23:609–10.
14. Schurch B, de Sčze M, Denys P et al. Botulinum toxin type A is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol 2005;174:196–200.
15. Schulte-Baukloh H, Knispel HH, Stolze T et al. Repeated botulinum-A toxin injections in treatment of children with neurogenic detrusor overactivity. Urology 2005;66:865–70.
16. Gill DM. Bacterial toxins: a table of lethal amounts. Microbiol Rev 1982;46:86–94.
17. Simpson LL. Molecular pharmacology of botulinum toxin and tetanus toxin. Annu Rev Pharmacol Toxicol 1986;26:427–53.
18. Reitz A, Schurch B. Botulinum toxin type B injection for management of type A resistant neurogenic detrusor overactivity. J Urol 2004;171(2 Pt 1):804–5.
19. Meunier FA, Schiavo G, Molgo J. Botulinum neurotoxins: from paralysis to recovery of functional neuromuscular transmission. J Physiol Paris 2002;96: 105–13.
20. Apostolidis A, Popat R, Yiangou Y et al. Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J Urol 2005;174:977–82.
21. Sheean G. Botulinum toxin for the treatment of musculoskeletal pain and spasm. Curr Pain Headache Rep 2002;6:460–9.
22. Dykstra DD, Pryor J, Goldish G. Use of botulinum toxin type B for the treatment of detrusor hyperreflexia in a patient with multiple sclerosis: a case report. Arch Phys Med Rehabil 2003;84:1399–400.
23. Bagi P, Biering-Sorensen F. Botulinum toxin A for treatment of neurogenic detrusor overactivity and incontinence in patients with spinal cord lesions. Scand J Urol Nephrol 2004;38:495–8.
24. Hajebrahimi S, Altaweel W, Cadoret J et al. Efficacy of botulinum-A toxin in adults with neurogenic overactive bladder: initial results. Can J Urol 2005; 12:2543–6.
25. Ghei M, Maraj BH, Miller R et al. Effects of botulinum toxin B on refractory detrusor overactivity: a randomized, double-blind, placebo controlled, crossover trial. J Urol 2005;174:1873–7.
26. Harper M, Popat RB, Dasgupta R et al. A minimally invasive technique for outpatient local anaesthetic administration of intradetrusor botulinum toxin in intractable detrusor overactivity. BJU Int 2003;92: 325–6.
27. Popat R, Apostolidis A, Kalsi V et al. A comparison between the response of patients with idiopathic detrusor overactivity and neurogenic detrusor overactivity to the first intradetrusor injection of botulinum-A toxin. J Urol 2005;174:984–9.
28. Haferkamp A, Schurch B, Reitz A et al. Lack of ultrastructural detrusor changes following endoscopic injection of botulinum toxin type A in overactive neurogenic bladder. Eur Urol 2004;46:784–91.
29. Dmochowski R, Sand PK. Botulinum toxin A in the overactive bladder: current status and future directions. BJU Int 2007;99:247–62.
30. Karsenty G, Reitz A, Lindemann G et al. Persistence of therapeutic effect after repeated injections of botulinum toxin type A to treat incontinence due to neurogenic detrusor overactivity. Urology 2006;68: 1193–7.
31. Kalsi V, Popat RB, Apostolidis A et al. Cost-consequence analysis evaluating the use of botulinum neurotoxin- A in patients with detrusor overactivity based on clinical outcomes observed at a single UK centre. Eur Urol 2006;49:519–27.
32. Khera M, Somogyi GT, Salas NA et al. In vivo effects of botulinum toxin A on visceral sensory function in chronic spinal cord-injured rats. Urology 2005;66:208–12.
33. Vemulakonda VM, Somogyi GT, Kiss S et al. Inhibitory effect of intravesically applied botulinum toxin A in chronic bladder inflammation. J Urol 2005; 173:621–4.
34. Ranoux D, Gury C, Fondarai J et al. Respective potencies of Botox and Dysport: a double blind, randomised, crossover study in cervical dystonia. J Neurol Neurosurg Psychiatry 2002;72: 459–62.
35. Whurr R, Nye C, Lorch M. Meta-analysis of botulinum toxin treatment of spasmodic dysphonia: a review of 22 studies. Int J Lang Commun Disord 1998;33 Suppl:327–9.